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Chronic neuropathic pain affects approximately 8% of the total adult human 
population and comes with significant burden for both the patient and healthcare system [1]. 
Patients often experience reduced functionality, which, in many cases results in them being 
uncapable of working. Chronic neuropathic pain is typically characterized by a low health-
related quality of life; compared to other major diseases such as cancer, type-2 diabetes, and 
cardiovascular diseases, the health-related quality of life of patients with chronic neuropathic 
pain is significantly lower [2]. Because of the high prevalence of chronic neuropathic pain and 
the low health-related quality of life patients suffer from, chronic neuropathic pain forms a 
serious burden on both the healthcare system as well as the economy.  
The effectiveness of pharmacological treatment of chronic neuropathic pain is often 
very limited, with less than 50% of patients responding to therapy. Furthermore, 
pharmacological interventions are often accompanied by unacceptable side effects such as 
development of tolerance and addiction [3]. It is therefore that further optimization of 
chronic neuropathic pain treatment is needed and it is in this context that the present thesis 
focusses on the role and mechanisms of action of interventional neuromodulatory 
approaches.  
Interventional neuromodulation techniques such as spinal cord stimulation (SCS), 
dorsal root ganglion stimulation (DRGS) and pulsed radiofrequency (PRF) often provide a 
suitable therapy for refractory neuropathic pain patients [4-16]. Moreover, the side effects 
associated with these types of interventional treatments are typically less severe than those 
associated with many pharmacological treatment options [3]. However, despite the many 
advantages, these neuromodulation techniques do not come without limitations. A 
substantial group of patients treated with either SCS, DRGS or PRF still do not respond to 
treatment or experience a lack of treatment success over time. In this light it is of utmost 
importance to understand why, when and how chronic neuropathic pain patients do not 
respond to these treatments. A mechanism-based approach which allows understanding of 
the mechanisms of action of these neuromodulatory treatments might result in improved 
efficacy of these therapies.   
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SCS with conventional settings (Con-SCS) has been successfully used to treat chronic 
neuropathic pain for over 50 years. Over the last decade, several new stimulation waveforms 
and new stimulation targets (such as DRGS) have been introduced to the field of SCS in order 
to  further improve stimulation efficacy, while simultaneously eliminating some of the 
limitations with Con-SCS. One of the most prominent examples of innovation within the 
parameter space of SCS is the paresthesia-free Burst paradigm [17]. While indeed evidence 
suggests that Burst-SCS can yield superior pain relief compared to Con-SCS [17-19], especially 
related to the cognitive-affective dimensions of the pain experience, Burst-SCS still lacks the 
anatomic specificity (ability to stimulate difficult-to-reach areas such as the extremities and 
the groin) and stability (stable paresthesia intensity regardless of body position) of DRGS. 
Based on this knowledge, summarized in Chapter 2, we set out to combine for the first time 
the advantage of a new stimulation paradigm with a new location of SCS in an animal model 
of painful diabetic peripheral neuropathy (PDPN) in Chapter 3: burst stimulation of the dorsal 
root ganglion. From these experiments we concluded that while the maximum amount of 
pain relief was comparable between Con-DRGS and Burst-DRGS, Burst-DRGS, but not Con-
DRGS, showed a delayed wash-out effect, which might have serious implications for optimal 
stimulation delivery of Burst-DRGS as well as battery life of the IPG in clinical practice. In line 
with this, preclinical observations have been extended to the clinic, where further clinical 
studies have been performed on the efficacy of Burst ‘’microdosing’’, a paradigm that relies 
on the introduction of stimulation-off phases inbetween stimulation-on phases. From this it 
was concluded that Burst-SCS microdosing is as effective as standard Burst-SCS, while having 
significantly lower battery consumption (and thus fewer battery replacements for the pain 
patient) [20]. Whether or not such a microdosing approach can also be successfully utilized 
for Burst-DRGS remains to be studied. Interestingly, with the publication of our first 
preclinical study on Burst-DRGS in PDPN, one clinical study has been published utilizing Burst-
DRGS in neuropathic pain patients [21]. The authors found that at the end of the 18 months 
treatment period, 78% of patients preferred the Burst-DRGS protocol over the Con-DRGS 
protocol. Burst-DRGS is currently being assessed formally, however, in a RCT that is under 
way (ClinicalTrials.gov identifier: NCT03318250).  
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Previous studies have indicated that Burst-SCS can be further optimized by adjusting 
relevant stimulation parameters, such as amplitude, in order to modulate the amount of 
charge delivered to the nervous system [22]. In Chapter 4, we titrated the optimal stimulation 
amplitude for Burst-DRGS to approximately 52% of the motor threshold (MT), and found a 
nonlinear relation between Burst-DRGS amplitude and pain behavior outcome. Combined 
with the results of Chapter 3, these results allowed us to further optimize Burst-DRGS to give 
a form of stimulation that delivers maximum pain relief, while at the same time minimizing 
battery consumption. As the chronic pain patient is likely to benefit from such an optimized 
treatment, future clinical studies should aim to verify these findings. 
Besides the titration of optimal stimulation parameters, another important aspect 
for optimizing DRGS therapy is understanding its underlying mechanism of action. From the 
field of SCS we know that the presence of the neurotransmitter GABA in the dorsal horn of 
the spinal cord plays an important role in its mode of action [23-27]. This even led to 
translation to the clinic, where baclofen, a GABAB receptor agonist was used to rescue initial 
nonresponders to SCS, and turn them into responders [28, 29]. Similarly, gaining more insight 
into the mechanisms of action underlying DRGS might lead to improved treatment of the 
chronic neuropathic pain patient. While it was recently shown that DRGS is not likely to rely 
on the release of GABA in the dorsal horn of the spinal cord [30], it is possible that local, 
GABAergic signaling in the DRG is involved [31]. In Chapter 5, we therefore tested the 
hypothesis that a second GABAergic gate is responsible for the pain relieving effect of DRGS. 
Based on our immunohistochemical findings, we found no evidence for such a GABAergic 
gate located in the DRG. Still, we consider the presentation of these data to be of great 
importance, as publishing bias (skewed towards positive findings) is an important problem 
that the academic community has to deal with. Based on this work, we can now look for 
alternative modes of action of DRGS to further improve DRGS therapy for the pain patient. 
In the last part of the thesis (Chapter 6) the efficacy of a PRF treatment adjacent to 
the DRG on experimental chronic neuropathic pain is investigated and described. 
Fundamentally, PRF greatly differs from DRGS in the way it is delivered (once vs continuous 
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delivery of current), something that is also expressed in the differences between the duration 
and amount of pain relief obtained with these two therapies. We showed that treatment 
with PRF to the DRG significantly attenuated mechanical and thermal hypersensitivity, albeit 
to lesser extent than DRGS (Chapter 3 and 4), whereas no effect was observed on pain-
related gait using the CatWalk system. With our study, previous findings [32] related to the 
pain relieving effect of PRF were confirmed, something which is important when establishing 
a reproducible and valid animal model for studying the effects end mechanisms of action of 
a given treatment. At the same time, our, and previous [33] data strongly suggests that 
CatWalk gait analysis does not allow to detect or analyze behavioral effects of interventional 
treatment approaches such as PRF and SCS in the chronic experimental PSNL model. 
Nevertheless, studying behavioral effects (short or long-lasting) is still an issue in the 
experimental pain field and may make the impact of pain relieving effects and the 
interpretation and translation of findings to the clinic very difficult. To date, reflex-based 
outcome measures such as mechanical hypersensitivity (e.g. Von Frey test) and thermal 
hypersensitivity (e.g. Hargreaves test) are considered to be the golden standard in 
experimental pain research. However, as these tests are rather subjective and rely on evoked 
nociception instead of spontaneous pain, they are not optimal. Future studies should 
therefore aim to include more operant-like tests that also take into account the affective-
emotional and cognitive aspects of pain in order to improve the translational significance of 
preclinical observations. 
From a practical point of view, the results presented in this academic thesis provide 
strong arguments for continuing experimental research on the efficacy and mechanisms of 
action of neuromodulation of the DRG in experimental chronic neuropathic pain. This should 
then be based on an orchestrated interplay between reproducible experimental animal 
studies and well-designed large, (preferably) non-industry initiated clinical trials. Given the 
fundamental differences in terms of efficacy and duration of pain relief between DRGS and 
PRF, they are very likely to depend on different mechanisms of action. By gaining more insight 
into these mechanisms of action, the efficacy of interventional pain treatments for the 
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chronic neuropathic pain patient might significantly increase, thereby reducing the societal 
and economic burden of chronic neuropathic pain as a disease. 
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